Four companies are expected to have UK marketing authorisations for generic weight loss medicines following the expiry of liraglutide’s patent
The British Generic Manufacturers Association (BGMA) has stated that while the genericisation of GLP-1 weight loss medicines can potentially deliver important public health benefits, including improved access to treatments and cost savings, it must be done in “a responsible way.”
In a report released on Thursday, the trade body representing off-patent medicines outlined four key recommendations for policymakers, payers, and regulators to consider as these medicines become more widely available, aimed at supporting “safe and sustainable growth.”
First, it recommended that generic weight loss medicines remain prescription-based and not be made available as over-the-counter (OTC) products.
“This should be the case whether they are obtained privately through a high street pharmacy, a solely online pharmacy for example, or prescribed via the NHS,” the trade body noted, urging sellers to ensure that patients have regular GP consultations and can report any concerns.
Secondly, the BGMA urged the government and the NHS to clearly communicate to patients that these medicines are “to be taken as part of a broader focus on improved diet and increased exercise.”
It emphasised that these medicines alone cannot deliver lasting and sustainable weight loss.
“For these medicines to deliver not only patient benefits but also reduce the need from the broader healthcare system, the government should follow Nourishing Britain’s recommendations, and education must be put in place to encourage patients to use weight loss medicines as part of other changes to their lifestyles and habits,” it stated Read More….
Comments